PPGN.SW Stock — Price, Charts & Analysis

PolyPeptide Group AG (PPGN.SW) has a trailing P/E of 107.20x and a forward P/E of 30.56x. This places PPGN.SW in a premium earnings multiple territory based on the valuation data currently available on Worldtickers.

PPGN.SW trades with 107.20x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether PPGN.SW looks overvalued or undervalued.

PPGN.SW's P/E of 107.20x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

PPGN.SW's trailing EPS is CHF 0.41 and forward EPS is CHF 1.44.

EPS, or earnings per share, shows how much profit PolyPeptide Group AG generated for each share. PPGN.SW's trailing EPS is CHF 0.41, and investors usually prefer EPS that is positive and growing over time.

PolyPeptide Group AG has a market cap of CHF 1.45B, making PPGN.SW a small-cap stock based on the current market value shown on Worldtickers.

PPGN.SW's latest stock price on Worldtickers is CHF 43.95. The latest move is -CHF 0.05 or -0.11%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

PPGN.SW's quote includes a latest price of CHF 43.95. The market open is CHF 44.00. Previous close is CHF 44.00. The intraday range is CHF 43.95 to CHF 44.05.

PPGN.SW is down in the latest quote, with a move of -CHF 0.05 or -0.11%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

PPGN.SW generated CHF 458.86M in trailing revenue. Revenue growth is 41.60%, which helps show whether demand is expanding or slowing.

PPGN.SW's revenue growth is 41.60%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, PPGN.SW shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is CHF 14.45M.

Gross margin is 22.86%. Margins show how efficiently PolyPeptide Group AG turns revenue into profit.

PolyPeptide Group AG carries CHF 149.21M and holds CHF 59.03M in cash.

PPGN.SW holds CHF 59.03M on its balance sheet.

PPGN.SW's book value per share is CHF 9.62.

Institutions hold 14.73% of PPGN.SW shares. Insiders hold 60.52% of shares. Ownership mix helps investors understand how much of PolyPeptide Group AG is held by professional investors and company insiders.

PPGN.SW has 33.02M shares outstanding. Float shares are 12.97M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for PPGN.SW, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for PPGN.SW is CHF 1.44. Revenue growth is 41.60%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

PPGN.SW's trailing EPS is CHF 0.41. Forward EPS is CHF 1.44. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

PPGN.SW is in the Healthcare sector. Its earnings multiple is 107.20x. Its latest displayed growth metric is 41.60%. Compare these figures with sector peers before deciding whether PolyPeptide Group AG is stronger or weaker than average.

PPGN.SW trades at CHF 43.95. The stock trades at 107.20x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of PolyPeptide Group AG's fundamentals.

PPGN.SW risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 1.00, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

PPGN.SW should be compared with companies in Drug Manufacturers - Specialty & Generic. Its earnings multiple is 107.20x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

PolyPeptide Group AG (PPGN.SW) operates in Healthcare, specifically Drug Manufacturers - Specialty & Generic. PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services.

PPGN.SW trades on Swiss. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

PPGN.SW stock is priced in CHF on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

PolyPeptide Group AG's official website listed on Worldtickers is www.polypeptide.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

PolyPeptide Group AG employs about 1.46K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

PolyPeptide Group AG is headquartered in Baar, Switzerland. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

PPGN.SW is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

PPGN.SW has traded between CHF 21.80 and CHF 50.10 over the past 52 weeks. At CHF 43.95, it is 12.28% below the high and 101.61% above the low. The 52-week range helps gauge long-term price momentum.

PPGN.SW is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is CHF 43.44 and its 200-day moving average is CHF 32.65.

PPGN.SW's RSI is 51.42. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

PPGN.SW's latest RSI reading is 51.42, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for PPGN.SW is near CHF 43.70. Key resistance is near CHF 44.10. Breaks above resistance or below support can change the short-term technical setup.

PPGN.SW's nearest reported support level is CHF 43.70. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

PPGN.SW's nearest reported resistance level is CHF 44.10. A breakout above resistance can improve momentum, especially when volume confirms the move.

PPGN.SW trades about 113.59K shares daily on average. The latest displayed volume is 174.75K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

PPGN.SW's MACD is -0.06, which is a negative momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

PPGN.SW is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 51.42 (neutral). MACD is bearish. Nearest support is around CHF 43.70. Resistance is around CHF 44.10. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is CHF 43.91 (0.21% from price). MA50 is CHF 43.44 (1.29% from price). MA200 is CHF 32.65 (34.77% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. PPGN.SW's MA20 is CHF 43.91. MA50 is CHF 43.44. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

PPGN.SW's pivot is near CHF 44.02. Support is near CHF 43.70. Resistance is near CHF 44.10. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for PPGN.SW is near CHF 41.63. The next upper resistance zone is near CHF 45.25. These levels help define risk and possible follow-through zones after a breakout or breakdown.

PPGN.SW's Bollinger range is roughly CHF 43.72 to CHF 44.10. Band width is near 0.86%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

PPGN.SW's ATR-based typical daily range is about 1.18%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 174.75K shares. Average volume is about 113.59K shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

PPGN.SW's all-time high shown on Worldtickers is CHF 147.40. Its all-time low is CHF 13.22. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

PPGN.SW has a beta of 1.00, meaning it has historically been more volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.